Erythroid-specific Human Factor IX Delivery From In Vivo Selected Hematopoietic Stem Cells Following Nonmyeloablative Conditioning in Hemophilia B Mice
Open Access
- 1 October 2008
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 16 (10), 1745-1752
- https://doi.org/10.1038/mt.2008.161
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunityBlood, 2008
- Platelet‐delivered factor VIII provides limited resistance to anti‐factor VIII inhibitorsJournal of Thrombosis and Haemostasis, 2008
- Enhanced Gene Expression Conferred by Stepwise Modification of a Nonprimate Lentiviral VectorHuman Gene Therapy, 2007
- Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimensBlood, 2007
- Hematopoietic Stem Cells Encoding Porcine Factor VIII Induce Pro-coagulant Activity in Hemophilia A Mice with Pre-existing Factor VIII ImmunityMolecular Therapy, 2007
- The Genetic Engineering of Hematopoietic Stem Cells: the Rise of Lentiviral Vectors, the Conundrum of the LTR, and the Promise of Lineage-restricted VectorsMolecular Therapy, 2007
- Angiogenesis Enhances Factor IX Delivery and Persistence from Retrievable Human Bioengineered Muscle ImplantsMolecular Therapy, 2006
- Recombinant factor VIII expression in hematopoietic cells following lentiviral transductionGene Therapy, 2003
- Lentiviral Vectors for Enhanced Gene Expression in Human Hematopoietic CellsMolecular Therapy, 2000
- Vitamin K-Dependent Carboxylase: mRNA Distribution and Effects of Vitamin K-Deficiency and Warfarin TreatmentBiochemical and Biophysical Research Communications, 1996